#United States #San Diego #Car Technology #biomedical innovation #CREATE Medicines

CREATE Medicines Showcases Advanced CAR Platforms at AACR 2026

CREATE Medicines, Inc., a pioneering biotechnology firm in clinical stages, is set to unveil significant advancements in its CAR T and CAR NK technologies at the prestigious American Association for Cancer Research (AACR) Annual Meeting 2026. This key event will take place in San Diego from April 17 to April 22, 2026.

The company will present two crucial posters that showcase their revolutionary multi-immune in vivo CAR platforms, featuring new insights into their RetroT technology. This all-mRNA genome integration platform is meant to deliver stable genetic changes without the use of viral elements, highlighting CREATE's commitment to safer cell therapies.

One of the standout features of the presented data is the simultaneous engineering of multiple immune cells—NK, T, and myeloid cells. Results from a colorectal cancer model demonstrated how tailored CAR mRNAs can effectively diminish tumor growth while also remodeling the surrounding tumor microenvironment. Notably, RetroT's debut data illustrates the platform’s efficacy by showing that CAR T cells, engineered without double-strand breaks or viral vectors, significantly cut down tumor burdens in preclinical leukemia models.

Dr. Robert Hofmeister, the Chief Scientific Officer at CREATE, emphasized the purpose behind their research approach. He stated, "CREATE was built to rapidly iterate directly from our clinical data and unlock the clear advantages of in vivo cell therapy. Our presentations at AACR reinforce our platform's unique capabilities, which have been refined through extensive patient experience to develop next-generation therapies for oncology and autoimmune conditions."

This landmark presentation not only marks CREATE's compelling trajectory in CAR therapy but also establishes it as a leader in the in vivo immune cell engineering landscape. The company is recognized for advancing the broadest array of in vivo CAR therapies, supported by an extensive clinical data set gathered from over 50 patients. This extensive database enables remarkable speed in translating clinical insights into innovative and effective therapeutic pipelines.

AACR Poster Presentation Details

Title of Presentation: In Vivo CAR mRNA Engineering of T Cells and Myeloid Cells Enables Potent Anti-Tumor Control of Solid Cancers
Date: April 19, 2026
Time: 2–5 PM PT
Session Category: Immunology
Poster Board: 18

Title of Second Presentation: Stepwise In Vivo CAR T Cell Engineering via Transient RNA Programming and RetroT All-RNA Genome Integration
Date: April 20, 2026
Time: 9 AM–12 PM PT
Session Title: Late-Breaking Research Immunology 2
Poster Board: 20

With these promising advancements, CREATE Medicines aims to redefine the landscape of immunotherapy, driving progress in the development of effective, tailor-made treatments for various cancers and autoimmune diseases.

For more information on CREATE Medicines and their innovations, visit createmedicines.com. Stay connected through their social media channels on LinkedIn and Twitter for updates on their groundbreaking research and initiatives.